Skip to main content
Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2016 Nov 30;9:133. doi: 10.1186/s13045-016-0364-0

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

George S Laszlo 1, Todd A Alonzo 2,3, Chelsea J Gudgeon 1, Kimberly H Harrington 1, Alex Kentsis 4,5,6, Robert B Gerbing 3, Yi-Cheng Wang 3, Rhonda E Ries 1, Susana C Raimondi 3,7, Betsy A Hirsch 3,8, Alan S Gamis 3,9, Soheil Meshinchi 1,3,10, Roland B Walter 1,11,12,
PMCID: PMC5129595  PMID: 27903291

Erratum

The original article [1] contains an omission of information in the Financial support sub-section of the Declarations section.

The authors would like to acknowledge the Andrew McDonough B+ Foundation for financial support of co-author Dr Yi-Cheng Wang throughout this study, and regret this inadvertent omission from the original publication.

Footnotes

The online version of the original article can be found under doi:10.1186/s13045-015-0215-4.

Reference

  • 1.Laszlo GS, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Hematol Oncol. 2015;8:115. doi: 10.1186/s13045-015-0215-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES